Ammonium tetrathiomolybdate in the decoppering phase treatment of Wilson's disease with neurological symptoms: A case series
Abstract Objectives To present our experience with ammonium tetrathiomolybdate (ATTM) in the decoppering phase treatment of Wilson's disease (WD) with neurological symptoms. Methods An uncontrolled longitudinal study was carried out to describe a case series of five patients diagnosed of WD wit...
Main Authors: | Oriol De Fabregues, Jaume Viñas, Antoni Palasí, Manuel Quintana, Ignasi Cardona, Cristina Auger, Víctor Vargas |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-05-01
|
Series: | Brain and Behavior |
Subjects: | |
Online Access: | https://doi.org/10.1002/brb3.1596 |
Similar Items
-
Advances in Treatment of Wilson Disease
by: Annu Aggarwal, et al.
Published: (2018-02-01) -
Is Hydrogen Sulfide a Concern During Treatment of Lung Adenocarcinoma With Ammonium Tetrathiomolybdate?
by: Xiang Li, et al.
Published: (2020-02-01) -
MODERN ASPECTS OF PATHOGENETIC TREATMENT WITH ZINC SALTS OF PATIENTS WITH WILSON'S DISEASE IN UKRAINE
by: Ivan Voloshyn-Gaponov
Published: (2019-12-01) -
Advance in the pathogenesis and treatment of Wilson disease
by: Dong Qin-Yun, et al.
Published: (2012-11-01) -
Tetrathiomolybdate Treatment Leads to the Suppression of Inflammatory Responses through the TRAF6/NFκB Pathway in LPS-Stimulated BV-2 Microglia
by: Zhuo Wang, et al.
Published: (2018-02-01)